Management of toxicities with novel systemic therapies in UC

Thomas Flaig, MD

AURIC Director Thomas Flaig, MD, of the University of Colorado Anschutz Medical Campus in Aurora, Colorado, provides an overview of the management of toxicities with novel systemic therapies in patients with urothelial carcinoma (UC), highlighting the use of antibody-drug conjugates in advanced disease.

Continue reading